Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

PURPOSE: To determine the tolerability and serum concentration of epratuzumab, a humanized monoclonal antibody targeting CD22, administered alone and in combination with reinduction chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL), and to preliminarily assess tumor targeting...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Raetz, Elizabeth A., Cairo, Mitchell S., Borowitz, Michael J., Blaney, Susan M., Krailo, Mark D., Leil, Tarek A., Reid, Joel M., Goldenberg, David M., Wegener, William A., Carroll, William L., Adamson, Peter C.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2008
Materias:
Pediatric Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2654811/
https://ncbi.nlm.nih.gov/pubmed/18669463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.15.3528
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares